DBV Technologies S.A. develops treatment options for food allergies and other immunologic conditions as a late-stage biopharmaceutical company. Company updates center on the proprietary VIASKIN® patch technology, epicutaneous immunotherapy, and the VIASKIN Peanut program for peanut-allergic toddlers and children.
Recurring developments include clinical data from the Phase 3 VITESSE study, annual and quarterly financial results, financing and warrant-related capital actions, leadership and governance changes, share and voting-rights disclosures under French market rules, and market information tied to DBVT American Depositary Shares.
As of July 31, 2020, the company reports a total of 54,927,187 shares outstanding. The total number of voting rights amounts to 54,927,187 gross and 54,867,787 net, after excluding shares without voting rights. This information is disclosed in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers for market transparency.